Lymed-D Tablet is a combination pharmaceutical formulation containing Bromelain (90mg), Diclofenac (50mg), Rutoside (100mg), and Trypsin Chymotrypsin (50000AU), designed to provide effective anti-inflammatory, analgesic, and fibrinolytic actions. Bromelain, a proteolytic enzyme derived from pineapple stems, exhibits anti-inflammatory and edema-reducing properties, facilitating the breakdown of protein-based inflammatory mediators. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. Rutoside, a bioflavonoid, enhances capillary strength and reduces vascular permeability, contributing to the reduction of edema and bruising. Trypsin Chymotrypsin, proteolytic enzymes, aid in the degradation of necrotic tissue and fibrin clots, promoting tissue repair and accelerating the resolution of inflammation. The synergistic action of these components makes Lymed-D Tablet suitable for managing acute and chronic inflammatory conditions such as musculoskeletal injuries, postoperative inflammation, and soft tissue trauma. It is recommended to be used under medical supervision, considering contraindications related to NSAIDs and enzyme hypersensitivity. Lymed-D Tablet offers a multifaceted approach to inflammation management, combining analgesic, anti-edematous, and fibrinolytic effects to enhance patient recovery and comfort.